Friday, December 14, 2007

Haven't been too active on this board recently.. but I see I'm starting to get some comments, so it's time to update some of my positions...

As I mentioned in a reply to a comment from imapedestrian, I've tearfully sold out of my CCUR position, and reallocated it to GNBT based upon Technicals and the perception that they are about to go Phase III on their Ora-lyn insulin delivery system..

I do remain skeptical about GNBT's CEO, Anna Gluskin, but I think that some of their directors will provide the necessary managerial credibility. Dr. Gerald Bernstein, a former president of the American Diabetes Association, is on their BOD, and would be an excellent "face-man" for the company when it comes time to do CNBC interviews. But even if he's operating behind the scenes, that's fine with me..

Anyway.. the chart for GNBT indicates we're very close to an inflection point on a rising wedge formation, which could lead to a breakout that takes the stock almost 75% higher to the $2.50/range within the next 30-60 days.

Daily chart:

Daily chart

Note the "golden cross" of the Moving Averages on the daily chart... Very bullish, IMO, although we may have a short-term pull-back consolidation.. Volume has been very good in recent weeks and it appears accumulation is occurring.

And when we look at the monthly chart, it becomes evident that the bollinger bands are definitely pinching, a further indicator of a future major move to be expected in the stock (hopefully upward.. ;0)

Monthly chart

As for DNDN.. I also, regretfully, was forced to sell that stock at a loss, and even now, with the recent news that FINALLY Congress is pushing for an investigation into the FDA decision on Provenge, the stock is trading below where I sold it at. All of that support that had been built into the stock over the past 6 months has now turned into resistance and it's going to require substantial news to overcome it.

Thus, under $8/share, DNDN is a very speculative trading vehicle.. But as I type this, I see the stock is trading at $7.70 on heavy volume (short covering, I suspect.. ;0)

The Scrutinizer